<DOC>
	<DOCNO>NCT00090896</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , CP-675,206 , work different way stimulate immune system stop tumor cell grow . Vaccines may make body build immune response kill tumor cell . Combining CP-675,206 vaccine therapy may cause strong immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose CP-675,206 give vaccine therapy treat patient stage III stage IV melanoma remove surgery .</brief_summary>
	<brief_title>CP-675,206 ( CTLA4-Blocking Monoclonal Antibody ) Combined With Dendritic Cell Vaccine Therapy Treating Patients With Stage III Stage IV Melanoma That Can Be Removed With Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety maximum tolerate dose anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody ( CTLA4-blocking monoclonal antibody ; CP-675,206 ) administer autologous dendritic cell pulse MART-1 antigen patient unresectable stage III stage IV melanoma . - Determine biological activity immune effect regimen patient . Secondary - Correlate CTLA4 genotype safety regimen and/or immune response patient . - Determine , preliminarily , efficacy regimen , term clinical benefit rate , patient . OUTLINE : This open-label , dose-escalation study anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody ( CTLA4-blocking monoclonal antibody ; CP-675,206 ) . Patients receive CP-675,206 IV day 0 , 28 , 60 , 90 autologous dendritic cell pulse MART-1 antigen intradermally day 0 , 14 , 28 . After day 120 , patient stable respond disease may receive additional dos CP-675,206 monthly absence disease progression unacceptable toxicity Cohorts 3-6 patient receive escalate dos CP-675,206 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 3-21 patient accrue study within 3-10 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Histologically confirm cutaneous mucosal melanoma , meet criterion 1 follow : Unresectable stage III disease ( locally relapse unresectable , intransit lesion , unresectable drain node ) Stage IV disease , metastatic 1 follow site : Skin , subcutaneous tissue , distant lymph node Lung Other visceral site lactic dehydrogenase ≤ 2 time upper limit normal ( unless due liver stasis ) De novo metastatic disease allow provided patient refuse standard approved stageappropriate therapy melanoma Measurable disease HLAA2.1 positive ( HLAA*0201 molecular subtyping ) MART1expressing tumor reverse transcription polymerase chain reaction immunohistochemistry No symptomatic brain metastasis and/or progression CNS metastases within past 4 week Age 18 Performance status ECOG 01 OR Karnofsky 70100 % HIV negative Negative pregnancy test Fertile patient must use effective barrier contraception 3 month study participation More 30 day since prior immunotherapy metastatic , relapse , primary melanoma More 30 day since prior chemotherapy metastatic , relapse , primary melanoma More 4 week since prior corticosteroid More 30 day since prior radiotherapy metastatic , relapse , primary melanoma More 30 day since prior surgery metastatic , relapse , primary melanoma . More 30 day since prior therapy metastatic , relapse , primary melanoma More 14 day since prior antiinfective therapy More 4 week since prior immune suppressive therapy ( e.g. , cyclosporine ) chronic hepatitis B C asthma inflammatory bowel disease celiac disease history chronic colitis chronic gastrointestinal condition associate diarrhea bleed active chronic inflammatory autoimmune disease , include follow : Psoriasis Rheumatoid arthritis Multiple sclerosis Hashimoto 's thyroiditis Addison 's disease Graves ' disease Systemic lupus erythematosus active infection OR fever 100° F within past 3 day allergy study drug pregnant symptomatic seizure medical problem would preclude study participation prior melanoma immunotherapy contain MART1 antigen prior antiTcell therapy prior anticytotoxic Tlymphocyteassociated antigen4 monoclonal antibody ( CP675,206 ) organ allografts require longterm immune suppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>